KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Restructuring: 2018-2019

Historic Cash from Restructuring for Arbutus Biopharma (ABUS) over the last 2 years, with Dec 2019 value amounting to -$983,000.

  • Arbutus Biopharma's Cash from Restructuring fell 111.76% to -$66,000 in Q4 2019 from the same period last year, while for Dec 2019 it was -$983,000, marking a year-over-year decrease of 159.04%. This contributed to the annual value of -$983,000 for FY2019, which is 173.85% down from last year.
  • Latest data reveals that Arbutus Biopharma reported Cash from Restructuring of -$983,000 as of FY2019, which was down 173.85% from $1.3 million recorded in FY2018.
  • Arbutus Biopharma's 5-year Cash from Restructuring high stood at $1.3 million for FY2018, and its period low was -$983,000 during FY2019.
  • Moreover, its 2-year median value for Cash from Restructuring was $174,000 (2018), whereas its average is $174,000.
  • Data for Arbutus Biopharma's Cash from Restructuring shows a maximum YoY crashed of 173.85% (in 2019) over the last 5 years.
  • Yearly analysis of 2 years shows Arbutus Biopharma's Cash from Restructuring stood at $1.3 million in 2018, then crashed by 173.85% to -$983,000 in 2019.